Arrowhead Research Corporation

ARWRNASDAQ • USD
ThemeGenomics & Precision Med.›RNA Therapeutics
70.44 USD
↘ 1.38 (1.92%)🟢LIVE (AS OF 02:50 PM EDT)
🟢Market: OPEN

Arrowhead Research Corporation (ARWR) is currently trading at $70.44. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 15, 2026.

Open?$70.92
High?$72.94
Low?$69.90
Prev. Close?$71.82
Volume?1.5M
Avg. Volume?2.4M
VWAP?$71.30
Rel. Volume?0.62x
Bid / Ask
Bid?$70.29 × 100
Ask?$70.50 × 100
Spread?$0.21
Midpoint?$70.40
Valuation & Ratios
Market Cap?10.1B
Shares Out?140.9M
Float?135.6M
Float %?96.2%
P/E Ratio?N/A
P/B Ratio?16.48
EPS?-$2.14
Dividend?0.41%
Ex-Dividend?N/A
News
Profile
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Themes
Healthcare - Genomics & Precision Medicine›RNA TherapeuticsBiotech - Drug Development›Rare Disease Therapeutics
Employees
711
Market Cap
10.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arrowheadpharma.com
Listed
1995-02-01
Address
177 E COLORADO BLVD
PASADENA, CA 91105
Phone: 626-696-4702
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
80
Momentum?
35
Short Sent.?
85
Piotroski F-Score?1/9Weak
Altman Z-Score?3.34Safe
Confidence?59%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?6.22%Elevated
Short Interest?8.4M
Days to Cover?2.2
Free Float135.6M
Avg Daily Volume3.8M
Settlement Date2026-06-30
Financial Health
Current Ratio?6.23Strong
Quick Ratio?6.23Strong
Cash Ratio?0.64Adequate
Debt/Equity?1.44Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
10
16.48HIGH▾
P/S?
Peers
100
S&P
3
16.26HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-55.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
17.38HIGH▾
Returns & Efficiency
ROE?
S&P
3
-49.0%WEAK▾
ROA?
S&P
3
-13.3%WEAK▾
Cash Flow & Enterprise
FCF?$-50872000
Enterprise Value?$10.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist